Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel intensification trial in metastatic hormone-sensitive prostate cancer with suboptimal PSA response after 6 months of hormonal therapy
ISRCTN17215075Phase 3Recruiting
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Aug 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of docetaxel, abiraterone, enzalutamide and darolutamide in Metastatic Prostate Cancer (mPC) (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoints: Overall survival in all patients and Overall survival in Decipher Prostate classifier High subgroup. Started Aug 2026; status: recruiting.
02
Drugs
docetaxelabirateroneenzalutamidedarolutamide
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on ISRCTN17215075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17215075.